The UF Health Cancer Center will be representing at the American Society of Hematology (ASH) Annual Meeting that will be held virtually on Dec. 5-8, 2020.
The ASH Annual Meeting is the most comprehensive hematology event of the year. The meeting will provide an invaluable educational experience and overview of the latest scientific highlights in hematology. ASH is a great opportunity for hematology/oncology researchers to engage with your colleagues and network with more than 25,000 hematology professionals from every sub-specialty.
The full conference program is available here.
UF at ASH 2020
All University of Florida Presenters
Oral Presentations
Dec. 5
NSD2-E1099K Mutation Leads to Glucocorticoid-Resistant B Cell Lymphocytic Leukemia in Mice
Authors Include: Jianping Li, M.D., Jonathan Licht, M.D.
10:45-11 a.m.
Impact of Cryopreservation of Donor Grafts on Outcomes of Allogeneic Hematopoietic Cell Transplant (HCT)
Authors Include: Jack W. Hsu, M.D., Nosha Farhadfar, M.D., Hemant S. Murthy, M.D., John Wingard, M.D.
12:45-1 p.m.
CAR2.0 Therapy for the Management of Post-Transplantation Relapse of B-Cell Acute Lymphoblastic Leukemia
Authors Include: Biljana N. Horn, M.D., and Lung-Ji Chang, Ph.D.
12:45-1 p.m.
Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative
Authors Include: Nosha Farhadfar, M.D.
2:15-2:30 p.m.
508. Bone Marrow Failure: Advancing Our Biologic Understanding in Inherited and Acquired Bone Marrow Failure Disorders
Authors Include: Paul Castillo, M.D.
2-3:30 p.m.
Dec. 7
Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)
Authors Include: Biljana N. Horn, M.D.
8:15-8:30 a.m.
Junior Faculty Career Development Education Session
Speakers Include: Martina Murphy, M.D.
11:20-11:30 a.m.
Nelfinavir Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma By Modulating Membrane Lipid Bilayer Composition and Fluidity
Authors Include: Amin Sobh, Ph.D., and Chris D. Vulpe, M.D., Ph.D.
12:45-1 p.m.
Poster Presentations
Dec. 5
Identification of Pharmacogenomic Single Nucleotide Polymorphism Variants As Contributors to Toxicity Phenotype in the Treatment of Acute Childhood Leukemia
Authors Include: Biljana N. Horn, M.D., and Jatinder K Lamba, MSc, Ph.D.
Adenylate Kinase 2 Is a Selective Dependency in NSD2-High Multiple Myeloma
Authors Include: Amin Sobh, Ph.D., Charlotte Kaestner, Jianping Li, M.D., Alberto Riva, Ph,D., Richard Lynn Bennett, Ph.D., and Jonathan Licht, M.D.
Changing Molecular Diagnostic Testing Patterns for Patients (Pts) with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) in the Connect® MDS/AML Disease Registry
Authors Include: Christoper Cogle, M.D.
The Impact of COVID-19 on Hematology-Oncology Fellowship Programs: Program Director Perspectives
Authors Include: Martina Murphy, M.D.
Dec. 6
HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma—Age Subgroup Analysis of Elderly Patients
Authors Include: John Hiemnez, M.D.
Interactions with a “Humanized” Mesenchymal Bone Marrow Stromal Niche In Vivo Modify the Patterns of Essential Genes for Myeloma Cells: Therapeutic Implications
Authors Include: Jonathan Licht, M.D.
Functional Genomic Characterization of Endoplasmic Reticulum-Associated Dependencies in Multiple Myeloma – Biologic and Therapeutic Implications
Authors Include: Jonathan Licht, M.D.
Measuring the Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment
Authors Include: Martina Murphy, M.D.
Anticoagulant Usage Patterns for Acute Venous Thromboembolism in Patients with Advanced Liver Disease
Authors Include: Amar H Kelkar, M.D.
POU2AF1 As a Master Regulator of Oncogenic Transcription Factor Networks in Myeloma
Authors Include: Jonathan Licht, M.D.
Post-Remission Treatment (Tx) Patterns for Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the Connect® MDS/AML Disease Registry
Authors Include: Christopher Cogle, M.D.
Dec. 7
An Ara-C, Daunorubicin, and Etoposide microRNA (ADEmiR) Score As a Prognostic Tool to Predict AML Treatment Outcomes
Authors Include: Nam K Nguyen, M.S., PharmD
Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Authors Include: Christopher Cogle, M.D.
KDM6A Controls Genes Modulating Immune Surveillance in Multiple Myeloma
Authors Include: Daphne Dupere-Richer, Ph.D., Sayantan Maji, Ph.D., Alberto Riva, Ph.D., Gabrielle Quickstad, Darby Monagle, Richard Lynn Bennett, Ph.D., and Jonathan Licht, M.D.
Sex-Based Disparities in Outcome in Childhood Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group (COG) Report
Authors Include: Zhiguo Chen
Use of Olfactory Receptor Genes As Controls for Genome-Scale CRISPR Functional Genomic Studies to Define Treatment Resistance Mechanisms
Authors Include: Jonathan Licht, M.D.
